A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Title:
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Author:
Manzo, Julia Puhalla, Shannon Pahuja, Shalu Ding, Fei Lin, Yan Appleman, Leonard Tawbi, Hussein Stoller, Ronald Lee, James J. Diergaarde, Brenda Kiesel, Brian F. Yu, Jing Tan, Antoinette R. Belani, Chandra P. Chew, Helen Garcia, Agustin A. Morgan, Robert J. Wahner Hendrickson, Andrea E. Visscher, Daniel W. Hurley, Rachel M. Kaufmann, Scott H. Swisher, Elizabeth M. Oesterreich, Steffi Katz, Tiffany Ji, Jiuping Zhang, Yiping Parchment, Ralph E. Chen, Alice Duan, Wenrui Giranda, Vincent Shepherd, Stacie P. Ivy, S. Percy Chu, Edward Beumer, Jan H. ,